Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TCT In Brief

This article was originally published in The Gray Sheet

Executive Summary

Abbott bioabsorbable stent 30-day success rate is 94%: Everolimus-eluting, bioabsorbable BVS coronary stent achieves 93.5% delivery success rate with no major adverse cardiac events or stent thrombosis at 30-day follow-up. Results of Abbott's ABSORB trial, for BVS use in single, de novo, native coronary vessels, were presented Oct. 24 at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C., by principal investigator John Ormiston, MD, Auckland City Hospital, New Zealand. The stent demonstrated 7% recoil - "very similar to the recoil of a metallic stent," Ormiston said. Raimund Erbel, MD, University Duisburg-Essen, Germany, cautioned that the durability of polymer stent radial strength remains a concern because the polymers degrade over time (1"The Gray Sheet" April 10, 2006, p. 16)...

You may also be interested in...



Abbott’s SPIRITs Are Raised By Positive Drug-Eluting Stent Data At ACC

Abbott's SPIRIT III trial for its Xience V everolimus-eluting stent bodes well for the device's market potential and points to a new direction for stent manufacturers' premarket relationship with FDA

Abbott’s SPIRITs Are Raised By Positive Drug-Eluting Stent Data At ACC

Abbott's SPIRIT III trial for its Xience V everolimus-eluting stent bodes well for the device's market potential and points to a new direction for stent manufacturers' premarket relationship with FDA

Carotid Stent Firms See Another Step Into Market With Expanded Coverage

Carotid artery stent manufacturers hope to maintain momentum in an evolving market in which they see significant potential for growth

Related Content

UsernamePublicRestriction

Register

MT024141

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel